Hello, Welcome to Shine Consultant !
Summit & Event Shine Speaker Bureau Shine Advisor Shine Event Service
  • Summit & Event :
    With field research of markets and industries which is analyzed from a global strategic perspective by our professional teams, as well as hot topics which interest leadership and management, Shine Consultant provides you with one-stop platform of dialogue, practice -sharing and social network!
  • Shine Speaker Bureau:
    Committed to provide keynote speakers, executive learning masterclasses and boardroom advisory for global enterprises and institutions, each service provides a deeper and more interactive experience, especially for small, selected audiences and key individuals. We have the resources of the most influential business leaders and experts, who are the most outstanding representatives in their fields. Our team consists of experienced speech and event managers, and we focus on building long-term and in-depth partnerships.
  • Shine Advisor:
    As world-class insight network, we connects clients-decision makers with vetted subject matter experts-advisors. Our clients leverage the insights and perspectives shared by our advisors to stay informed and make better business decisions.We have over 600,000 Shine Advisors in 20 industries, which continues to grow every day.
  • Shine Event Service:
    Committed to be the world's most professional provider of industrial Summit & Event. We provide one-stop professional services, including investigating and planning, on-demand inviting, marketing and promoting, operating, project management, live& digital conference, each service is performed by an experienced professional team matched with long-term industrial resources. We focus on establishing long-term and in-depth partnerships.
Guest Information
发布时间: 2020 - 08 - 15
点击次数: 0
Positions: Partner
Company: Global Law Office
个人简介:
Alan Zhou is a lead partner in the Life Sciences and Healthcare practice of Global Law Office, with his strong background in Life-Sciences & Healthcare (L&H) practice. He focuses in M&A, regulatory compliance, and general corporate. As a participant or as an external counsel, Mr. Zhou has been engaged by local authorities and industrial associations for advising on legislation and industrial standard in L&H industry, topics of which including online hospital, digital marketing, medial insurance reform, medical representative management, and other compliance topics. Mr. Zhou has been honored by many internationally renowned institutions such as Chambers and Partners, Legal500, and China Business Law Journal as the Top-tier lawyer in L&H and compliance for many years.Prior to joining Global, Alan’s position was General Counsel in Greater China of Boehringer Ingelheim - a leading international pharmaceutical company for many years.
发布时间: 2020 - 05 - 27
点击次数: 0
Positions: VP LSPD-TT (MST)
Company: Top Ailliance
个人简介:
Takeda – Vitamins C Plant Start Up and Commissioning (Wilmington NC, 1990)Capacity limitations studies in producing Vitamin C. Extensive forensic analytical of spent electrolysis membranes, equipment controls optimization and improved electrolytic cell maintenance lead to a real capacity gain of 15% and an electrical efficiency improvement of 20%, resulting in over $1.2 million annual savings. Vitamin C – Hoffmann­La Roche (Belivedere NJ 1992)Distillation optimization studies and control system upgrades savings of $150k per year. In depth production data analysis of the final Vitamin C (6000 gal) reactor system was performed to improve product recovery. 30% increase product recovery rates. Vitamin C precursor (NaDAG under O2, NaOH, Pd/C) batch catalytic system optimization. Creative retrofit design for a dual train ‘triple cascade’ continuous reactor train with extensive DCS modifications. Non­linear modeling studies. 30% increase in capacity, 20% energy and material savings. $1.5 million per year. Acted as lead process control engineer in support for two major plant DCS retrofit projects ($45 million capital scope).  Proctor & Gamble Pharmaceuticals (Norwich NY 1998):Actonel (ResidronateNa) drug substance polymorph product quality studies to support $200 million revenue stream and launch at new European facility. Lead pilot plant and lab studies using crystallization theory and computational fluid dynamics modeling, to meet drug product registered release specifications. Peptide Synthesizer. Lead the design and commissioning of a new synthesizer unit ($400k, 20L reactor system) with a novel solvent recycle strategy. Developed low temperature batch reactor system ($300k, ­60 C) to support sensitive stereo selective reactions.  Imclone/Lilly BioPharmaceuticals (Branchburg NJ, 2004):Bioprocess manufacturing database datamart and visualization layer development. La300a: Tech transfer key lead support member for a novel therapeutic antibody for alzhiemers indication. Provided bioreaction engineering design for 11kL bioreactor systems where metabolic (OUR, CER) capacity increases of more than 100% were required. Erbitux cell culture improvements gained a 20% increase in cell culture titer and production performance. Technical bio-manufacturing lead for 3 oncological antibody clinical trial candidates.  Samsung Biologics (Incheon Korea, 2013):Director Manufacturing Technology Team. Introduction of three antibody products into production scale operation: ipilimumab (BMS), rituxan (Roche), and nivolumab (BMS).  Completed the Plant #1 process validation qualification campaign for ipilimumab (BMS), May 2014.  Teruisi Biologics (Huzhou China, 2015):VP Manufacturing. Bioprocess Plant design for Monoclonal Antibodies. Plant design, clean room design, plant validation strategy and design. Engineering contract and capital purchase contract management. Nikon Cell Innovation (Shinsuna, Tokyo Grand Harbor, Japan, 2017):Project Manager, MODA Environmental Monitoring System Implementation, new Cell and Gene Therapy production facility. Complete Computer System Validation design, validation strategy and qualification. BioThera Solutions, Ltd., Hedy Corp,(Gaungzhou, China 2018):Corporate leadership for late stage process development including GLP cell culture and protein purification process development and GLP/cGMP pilot scale pre-clinical supply and process scale-up. PD Department leader over three groups of 25 staff. Designed and commissioned new PD labs (1000 sqm). Late stage process QbD studies for 3 mAb global market biosimilars. Top Alliance Biopharm, Junshi (Wujiang, Jiangsu, China, 2017):Building new MST department for Late Stage Process Development and Technology Transfer. Oversight of buildout and commissioning of 2 process characterization labs (supporting DS and DP) focused on QbD/CMC process development functions, and continuing Manufacturing Technology and Sciences oversight for the commercialization of  late stage monoclonal antibody therapeutics JS001 and JS002. Applied statistical and data sciences oversight for bio-process development data systems and tools with SAS/JMP, R, R-Shiny, MySQL and other tools supporting process QbD.
发布时间: 2020 - 05 - 27
点击次数: 0
Positions: President & CSO
Company: Genor Biopharma Co. Ltd, Walvax Bio Group
个人简介:
Dr. Zhou Xinhua (Dr. Joe Zhou) is the President and Chief Scientist of Genor Biopharma. He has been selected as a national expert of the TOP 1000 TALENTS program in China since 2010. Dr. Zhou also is a visiting professor teaching Master Degree Program in International Pharmaceutical Engineering Management (IPEM) at Peking University, China. He is an invited vice-chair of Biopharmaceuticals Committee under China Pharmaceuticals Society, the Founder and first Chair of China Protein Drug Quality Alliance (CPDQA), the Founder and first Chair of Biological Drug Product and Process Committee of China ISPE, and the Founder and first Chair of Amgen Aluminums Association (AAA) in China. Previously, Dr. Zhou was Scientific Director at Amgen for bioprocess development and trouble shooting for bioprocess and bio-manufacturing. He has over 20-years industrial experience of process development, multiple project management capacity in cGMP and non-GMP reproducible purification/production of protein/antibody therapeutics from FIH to CPD with depth knowledge of CHO clone selection, cell culture optimization, viral clearance, real time analytical assays, formulation and product specification for drug substances and drug products.
发布时间: 2020 - 08 - 15
点击次数: 0
Positions: Senior Vice President of the Center of Project Pro
Company: Asymchem Group
个人简介:
Dr. Yi Hsiao joined AsymChem in September 2018 as Senior Vice President of the Center of Project Process R&D, in charge of process development, introduction and implementation of new technologies and integration of research, analytical and technology functions.  Dr. Hsiao received his Ph.D. degree in 1991 from Prof. Noyori (2001 Nobel laureate) at Nagoya University, Japan and performed postdoctoral studies at ERATO, Japan and at Colorado State University with Prof. L. Hegedus. In 1997, he joined the Process Research department of Merck, where he has defined and developed processes for a number of drug candidates. His work of development of the commercial synthesis of Januvia was recognized with the 2004 Solvias Ligand Prize, 2005 Astra Zeneca Award for Excelle==-O9IY7RESWzXDCGYHnce in Green Chemistry and 2006 Green Chemistry presidential award.In 2006, Yi moved to Process R&D in Bristol-Myers Squibb to build a new catalysis research group, introduced automated high throughput catalysis screening system and a knowledge management database. Dr. Yi Hsiao has published over 50 research papers and book chapters, over 40 presentations.  He is an organizing committee member of the 2018 International Forum of Reactions and Processes for Pharmaceutical Development and the industry co-chair of 2019 GRC-organic reactions and processes.